The tie up allows Envoy to use MBL’s RIP-Chip technology for its drug discovery and development purpose.
Under the agreement, Envoy is responsible to pay an upfront payment, annual licensing fees and milestone payments to MBL.
MBL president Katsuhiko Nishida said this agreement provides Envoy a freedom-to-operate condition of our technology as well as a complementary approach to discover novel drug targets.
"RIP-Chip technology can provide additional information to their drug discovery pipelines regarding MOA and/or toxicological information of new drugs," Nishida said.